Bailey does not currently manufacture and sell process mass spectrometers, it is involved in the research and development of a new mass spectrometer product, which it plans to introduce in 1999. It appears that the introduction of this product would result in increased competition in the process mass spectrometer market, leading to lower prices and increased innovation. ABB's proposed acquisition of Elsag Bailey would eliminate this significant source of future competition and leave the process mass spectrometer market highly concentrated for the foreseeable future.

Substantial barriers to new entry exist in the process gas chromatograph and process mass spectrometer markets. A new entrant into either of these markets would need to undertake the difficult, expensive and time-consuming process of developing and testing a product, establishing a track record for product quality, and developing a service and support network. Because of the difficulty of accomplishing these tasks, new entry into either the process gas chromatograph or process mass spectrometer market, other than Elsag Bailey's imminent introduction of a process mass spectrometer, could not be accomplished in a timely manner and is therefore unlikely to deter or counteract the anticompetitive effects resulting from the transaction.

The proposed Consent Order effectively remedies the acquisition's anticompetitive effects in the process gas chromatograph and process mass spectrometer markets by requiring ABB to divest the assets of the Analytical Division of Elsag Bailey's Applied Automation, Inc. subsidiary. Pursuant to the Consent Agreement, ABB is required to divest these assets no later than six (6) months from the date ABB signs the Consent Agreement. In the event that ABB fails to divest the assets of the Analytical Division within this six-month time frame, the Consent Agreement contains a ''crown jewel'' provision which allows the Commission to appoint a trustee to divest Elsag Bailey's entire Applied Automation, Inc. subsidiary.

In order to ensure that the acquirer of the divested assets has access to all of the employees currently involved in Elsag Bailey's process gas chromatograph and process mass spectrometer businesses, the Consent Agreement requires ABB to provide financial incentives for these individuals to accept employment with the acquirer. The Order also requires ABB to provide the Commission a report of compliance with the divestiture provisions of the Order within thirty (30) days following the date the Order becomes final, and every thirty (30) days thereafter until ABB has completed the required divestiture. Finally, an Agreement to Hold Separate signed by ABB requires that the Applied Automation Assets, which includes the Analytical Division Assets, be operated independently of ABB until the divestiture required by the Order is completed.

The purpose of this analysis is to facilitate public comment on the proposed Order, and it is not intended to constitute an official interpretation of the agreement and proposed Order or to modify in any way their terms.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 99–1179 Filed 1–19–99; 8:45 am]

BILLING CODE 6750–01–M

GENERAL SERVICES ADMINISTRATION

Federal Supply Service

Revisions to the General Services Administration's (GSA's) Centralized Household Goods Traffic Management Program (CHAMP)

AGENCY: Federal Supply Service, GSA.

ACTION: Notice of proposed program changes for comment.

SUMMARY: This notice invites comments on GSA's plan to increase the Centralized Household Goods Management Program's (CHAMP's) shipment surcharge from $45 to $105, and revise the Household Goods Tender of Service ''shipment definition'' as reflected in the attachment to this notice. The proposed new definition states that each of the three components of an individual employee's belongings (i.e., household goods, privately owned vehicle(s) (POV), and unaccompanied air baggage) is separately subject to the shipment surcharge. These actions are necessary to increase CHAMP funding and enable GSA to defray its expenses for this program.

DATES: Please submit your comments by February 19, 1999.

ADDRESSES: Mail comments to the Transportation Management Division (FBF), General Services Administration, Washington, DC 20406, Attn: **Federal Register** Notice. GSA will consider your comments prior to implementing these proposals.

FOR FURTHER INFORMATION CONTACT: Larry Tucker, Senior Program Expert, Transportation Management Division, FSS/GSA, 703–305–5745.

SUPPLEMENTARY INFORMATION: GSA's Centralized Household Goods Traffic Management Program (CHAMP) receives no Congressional funding and depends on a shipment surcharge, currently $45, to defray its costs. The shipment surcharge has been in effect since 1996 and no longer fully funds program expenses. So that GSA may meet its expenses and continue to provide these critical services, GSA proposes to increase the shipment surcharge to $105. GSA also plans to revise the shipment definition in the Household Goods Tender of Service to state that each of the three components comprising an individual employee's belongings (i.e.,) household goods, POV, and unaccompanied baggage) whether shipped separately or together is separately subject to a shipment surcharge.

GSA is committed to providing a program that meets the needs of Federal agencies. The funding increase proposed in this notice will be used to directly pay for program activities including: domestic and international rate negotiations, review and approval of carrier applications, consolidating carrier survey (3080) responses and computing the resulting customer satisfaction indices, providing technical assistance on questions pertaining to tariff interpretation and loss and damage claims, developing helpful move-related publications and training materials, and conducting workshops.

Dated: January 13, 1999.

Alan J. Zaic,

Assistant Commissioner, Office of Transportation and Property Management.

Existing HTOS Definition—1998–99 RFO, Section, 2–6.7.3 ''First Shipment. The first shipment of a relocation performed pursuant to the HTOS is defined as a surface shipment of household effects, shipment of a privately owned vehicle, and a shipment of unaccompanied air baggage, all or any one of which are tendered to the Participant by the shipping Federal Agency at the same time or within six months of the tender of the first component of this shipment.

''Supplemental Shipments. A supplemental shipment of a relocation performed pursuant to the HTOS is defined as any surface shipment, including a privately owned vehicle, or unaccompanied air baggage shipment tendered to the Participant by the shipping Federal Agency after six months from the date of the tender of the first component of the first shipment.''

Proposed Amendment to HTOS Shipment Definition. We are planning to revise the above referenced provision to read as follows:

''Definition of a shipment. For purposes of this HTOS, a shipment (whether on the same GBL or separate GBL's) is defined as:

(a) A surface shipment of household effects;

(b) Shipment of a privately owned vehicle; or

(c) Shipment of unaccompanied air baggage.

''This definition applies to interstate, intrastate and international shipments as defined in the applicable Request for Offers (RFO).

''Application of the shipment surcharge. The carrier will remit to GSA a shipment surcharge for each shipment equal to that provided in the GSA Request for Offers (RFO) for a specific rate-filing period. The shipment surcharge is due by the end of the quarter in which the carrier bills the agency for line haul and accessorial services, exclusive of storage-in-transit (SIT) charges as provided in paragraph 7–1.A. (9) a., above. The surcharge is not billable to the Federal agency and must be shown on the Original Public Voucher for Transportation Charges, SF 1113, as an allowance to the Government.''

[FR Doc. 99–1204 Filed 1–19–99; 8:45 am]

BILLING CODE 6820–24–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Amended Notice of Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Office of the Secretary, HHS.

ACTION: Notice of meeting.

The Advisory Committee on Blood Safety and Availability will meet on January 28, 1999 from 9 a.m. to 5 p.m. It was previously announced that the Committee would also meet on January 29, 1999. Since it no longer appears that the Committee will require two days to complete its agenda, the meeting is now scheduled to begin at 9 a.m. and conclude at 5 p.m. on January 29, 1999. The meeting will take place in the Crown Plaza Hotel, 14th and K Streets NW, Washington DC 20005. The meeting will be entirely open to the public.

As previously announced, the purpose of the meeting will be to discuss the options for implementation and evaluation of the recommendations made by the Advisory Committee regarding hepatitis C lookback at its November 24, 1998 meeting, and consideration of such Old and New Business as time permits.

Prospective speakers should notify the Executive Secretary of their desire to address the Committee and should plan for no more than 5 minutes of comment.

FOR FURTHER INFORMATION CONTACT: Stephen D. Nightingale, M.D., Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Safety, Department of Health and Human Services, 200 Independence Avenue SW, Washington, DC 20201. Phone (202) 690–5560; FAX (202) 690–6584; e-mail SNIGHTIN@osophs.dhhs.gov.

Dated: January 8, 1999.

Stephen D. Nightingale,

Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. 99–1155 Filed 1–19–99; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

President's Committee on Mental Retardation; Notice of Meeting

AGENCY HOLDING THE MEETING: President's Committee on Mental Retardation.

TIME AND DATE: February 20, 1999–11:00 a.m.–5:00 p.m.

PLACE: Renassiance Hotel, 999 9th Street, N.E., Washington, D.C. 20001.

STATUS: Full Committee Meetings are open to the public. An interpreter for the deaf will be available upon advance request. All meeting sites are barrier free.

TO BE CONSIDERED: The Committee plans to discuss critical issues concerning Federal Policy, Federal Research and Demonstration, State Policy Collaboration, Minority and Cultural Diversity and Mission and Public Awareness, relating to individuals with mental retardation.

The PCMR acts in an advisory capacity to the President and the Secretary of the U.S. Department of Health and Human Services on a broad range of topics relating to programs, services, and supports for persons with mental retardation. The Committee, by Executive Order, is responsible for evaluating the adequacy of current practices in programs and supports for persons with mental retardation, and for reviewing legislative proposals that impact the quality of life that is experienced by citizens with mental retardation and their families.

CONTACT PERSON FOR MORE INFORMATION: Jane L. Browning, 352–G Hubert H. Humphrey Building, 200 Independence Avenue, S.W., Washington, D.C. 20201–0001, (202) 619–0634.

Dated: January 12, 1999.

Jane L. Browning,

Executive Director, PCMR.

[FR Doc. 99–1203 Filed 1–19–99; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on February 24, 1999, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Rhonda W. Stover or John Schupp, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss new drug application (NDA) 21–036, zanamivir for inhalation (Relenza®, Glaxo Wellcome, Inc.), for the treatment of influenza A and B.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 17, 1999. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 17, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).